Predictive value of plasma TMB presented at 2021 ASCO-GI

Predicine is excited to partner with Canadian Cancer Trials Group (CCTG) and contribute to a 2021 Gastrointestinal Cancers Symposium featured presentation in pancreatic cancer. PredicineATLAS, a 600-gene cfDNA assay, is utilized in the CCTG PA.7 trial to assess the predictive value of plasma TMB which demonstrated predictive of benefit from the addition of AstraZeneca’s dual immune checkpoint inhibitors (durvalumab and tremelimumab) to Gemcitabine and nab-paclitaxel as first line therapy in metastatic pancreatic ductal adenocarcinoma (mPDAC).

View powerpoint presentation here.

Title: Predictive value of plasma tumor mutation burden (TMB) in the CCTG PA.7 trial: Gemcitabine (GEM) and nab-paclitaxel (Nab-P) vs. GEM, nab-P, durvalumab (D) and tremelimumab (T) as first line therapy in metastatic pancreatic ductal adenocarcinoma (mPDAC).
Speaker: Dr. Daniel Renouf, BC Cancer, University of British Columbia

Leave a Reply

11 − 2 =